Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of combined lidocaine, magnesium sulfate, and ketamine infusions for neuropathic pain
ACTRN12619000494134Phase 3Not yet recruiting
- Sponsor
- Daniel Ellyard
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lidocaine, magnesium sulfate and ketamine in Neuralgia, complex regional pain syndrome (CRPS) and fibromyalgia (FM), sponsored by Daniel Ellyard. Primary endpoint: Change in average pain score. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
lidocainemagnesium sulfateketamine
03
Conditions
Neuralgiacomplex regional pain syndrome (CRPS)fibromyalgia (FM)
Beyond the preview
Go deeper on ACTRN12619000494134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000494134.